BARD1germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma
Authors:
- 9 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (1) , 138-148
Abstract
High-risk neuroblastoma is a complex genetic disease that is lethal in over 50% of patients despite intense multimodal therapy. Through genome-wide association studies (GWAS) and next-generation sequencing (NGS), we have identified common single nucleotide polymorphisms (SNPs) and rare, pathogenic (P) or likely pathogenic (LP) germline loss-of-function (LOF) variants in BARD1 enriched in neuroblastoma patients. The functional implications of these findings remain poorly understood. We correlated BARD1 genotype with expression in normal tissues and neuroblastomas, along with the burden of DNA damage in tumors. To validate the functional consequences of germline P-LP BARD1 variants, we used CRISPR/Cas9 to generate isogenic neuroblastoma (IMR-5) and control (RPE1) cellular models harboring heterozygous BARD1 LOF variants (R112*, R150*, E287fs, and Q564*) and quantified genomic instability in these cells via NGS and with functional assays measuring the efficiency of DNA repair. Both common and rare neuroblastoma associated BARD1 germline variants were significantly associated with lower levels of BARD1 mRNA and an increased burden of DNA damage. Using isogenic heterozygous BARD1 LOF variant cellular models, we functionally validated this association with inefficient DNA repair. BARD1 LOF variant isogenic cells exhibited reduced efficiency in repairing Cas9-induced DNA damage, ineffective RAD51 focus formation at DNA double-strand break sites, and enhanced sensitivity to cisplatin and poly-ADP ribose polymerase (PARP) inhibition both in vitro and in vivo. Taken together, we demonstrate that germline BARD1 variants disrupt DNA repair fidelity. This is a fundamental molecular mechanism contributing to neuroblastoma initiation that may have important therapeutic implications.Keywords
Funding Information
- Howard Hughes Medical Institute
- National Institutes of Health (T32 GM008216)
- Alex’s Lemonade Stand
- EVAN Foundation
- Giulio D’Angio Endowed Chair
- National Cancer Institute
- National Institutes of Health (K08 CA230223, R35 CA220500, R01 CA204974, R01 CA237562)
- Ontario Ministry of Research and Innovation
- Canada Research Chair in Childhood Cancer Genomics
- St. Baldrick’s Foundation
- Damon Runyon Physician-Scientist
- Damon Runyon Cancer Research Foundation (PST-07-16)
This publication has 67 references indexed in Scilit:
- DELLY: structural variant discovery by integrated paired-end and split-read analysisBioinformatics, 2012
- Common Variation atBARD1Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and OncogenicityCancer Research, 2012
- Replication of Neuroblastoma SNP Association at the BARD1 Locus in African-AmericansCancer Epidemiology, Biomarkers & Prevention, 2012
- Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing dataBioinformatics, 2011
- Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cellsProceedings of the National Academy of Sciences, 2011
- BRCA1 Is Required for Postreplication Repair after UV-Induced DNA DamageMolecular Cell, 2011
- Mechanism of escape from nonsense-mediated mRNA decay of human β-globin transcripts with nonsense mutations in the first exonRNA, 2011
- Common variations in BARD1 influence susceptibility to high-risk neuroblastomaNature Genetics, 2009
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- Chromosome 6p22 Locus Associated with Clinically Aggressive NeuroblastomaNew England Journal of Medicine, 2008